Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$-183.48 Mln
EBITDA
$-189.52 Mln
Net Profit
$-180.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Surrozen Inc. Warrant (SRZNW)
| -6.1 | -12.6 | -58.8 | 60.8 | -53.3 | -- | -- |
|
BSE Sensex*
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
|---|---|
|
Surrozen Inc. Warrant (SRZNW)
| 10.2 |
|
S&P Small-Cap 600
| 7.0 |
|
BSE Sensex
| 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including... diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California. Read more
CEO, President & Director
Mr. Craig C. Parker M.B.A.
CEO, President & Director
Mr. Craig C. Parker M.B.A.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Surrozen Inc Warrant (SRZNW) is $0.02 (NASDAQ) as of 20-Jun-2025 16:00 EDT. Surrozen Inc Warrant (SRZNW) has given a return of -53.32% in the last 3 years.
Surrozen Inc Warrant (SRZNW) has a market capitalisation of -- as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Surrozen Inc Warrant (SRZNW) and enter the required number of quantities and click on buy to purchase the shares of Surrozen Inc Warrant (SRZNW).
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
The CEO & director of Mr. Craig C. Parker M.B.A.. is Surrozen Inc Warrant (SRZNW), and CFO & Sr. VP is Mr. Craig C. Parker M.B.A..
There is no promoter pledging in Surrozen Inc Warrant (SRZNW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Surrozen Inc. Warrant (SRZNW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Surrozen Inc Warrant (SRZNW) was $0 Mln.
$0.00
(
